Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130269 | 0.88 | KAT6A (0.33) | AKR1C3KAT6AS1PR5TDP1TYMS | |
| SCHEMBL3653744 | 0.83 | ADRB2 (0.35) | AKR1C3KAT6AS1PR5POLBTYMS | |
| SCHEMBL4125903 | 0.82 | NAMPT (0.38) | KAT6ATDP1NAMPT | |
| SCHEMBL4132668 | 0.81 | KAT6A (0.33) | KAT6ATYMSC1SKMT2A | |
| SCHEMBL3647496 | 0.80 | KAT6A (0.32) | KAT6AS1PR5C1SKMT2A | |
| SCHEMBL4125873 | 0.78 | CYP1A2 (0.33) | AKR1C3NAMPT | |
| SCHEMBL4119401 | 0.78 | KAT6A (0.44) | AKR1C3KAT6AMTNR1BTDP1KMT2A | |
| SCHEMBL4138207 | 0.78 | NAMPT (0.38) | TDP1NAMPTKMT2A | |
| SCHEMBL3647498 | 0.77 | C1S (0.33) | KAT6AC1S | |
| SCHEMBL4125700 | 0.77 | ALDH1A1 (0.38) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | AKR1C3 1218/4885KAT6A 4058/4885MTNR1A 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.